The BC Cancer Agency Radiotherapy (RT) program started the Prospective Outcomes and Support Initiative (POSI) at all six centres to utilize patient-reported outcomes for immediate clinical care, quality improvement, and research. Patient-reported outcomes were collected at time of computed tomography simulation via tablet and 2 to 4 weeks post-RT via either tablet or over the phone by a registered nurse. From 2013 to 2016, patients were approached on 20,150 attempts by POSI for patients treated with RT for bone metastases (52%), brain metastases (11%), lung cancer (17%), gynecological cancer (16%), head and neck cancer (2%), and other pilots (2%). The accrual rate for all encounters was 85% (n ¼ 17,101), with the accrual rate varying between the lowest and the highest accruing centre from 78% to 89% (P < .001) and varying by tumour site (P < .001). Using the POSI database, we have performed research and quality improvement initiatives that have changed practice.
Introduction
There is increasing evidence that Patient-Reported Outcome (PRO) use in clinical care can improve patient outcomes, including improved symptom control, increased supportive care measures, and patient satisfaction. 1, 2 Patient-reported outcomes are also increasingly used for research purposes as well-accepted outcomes in addition to more routine outcomes such as overall survival. [3] [4] [5] [6] However, collection of PRO can be cumbersome and costly and is therefore not widely adopted outside of research contexts. 1, [7] [8] [9] [10] [11] [12] [13] We sought to develop and test a clinically integrated population-based PRO collection and support program, capitalizing on a multidisciplinary team, which we called the Prospective Outcomes and Support Initiative (POSI). Here, we describe the initial implementation of PROs in the clinical setting by reporting the feasibility and clinical utility of PRO collection, both on an individual patient level and also for Quality Improvement (QI) initiatives and research on a population level.
Methods

History of the POSI
The BC Cancer Agency (BCCA) provides all Radiotherapy (RT) services in the province of British Columbia, Canada, within a publicly funded healthcare system. All RT is delivered within six regional centres situated in relatively urban cities, though a relatively large proportion of patients live in semiurban or rural regions and therefore receive their follow-up care remotely (eg, telehealth video conference), and return for in-person meetings, travelling up to 10 hours. [14] [15] [16] [17] In January 2012, the RT program leaders met to plan the direction of the program over the next several years, which resulted in a decision to pursue population-based collection of PRO across the RT program. Importantly, several members made it clear that the PRO must be available clinically and that an important component of the program must be to provide better support to patients before and after RT. Therefore, the POSI was endorsed by the provincial RT program ( Figure 1) .
As shown in Figure 1 , multiple steps were taken to maximize provincial engagement of all RT program staff. Importantly, a survey (n ¼ 371) was completed by the majority of RT program staff that demonstrated a high commitment to the concept of the initiative (91%, 80%, and 51% support if "no extra work," "a bit more effort," or "if considerable effort," where "effort" was defined as extra staff workload within the confines of the same workday and compensation). These survey results have been useful as POSI expands, as we remind RT program staff of their reported commitment to the initiative when there is hesitancy to expand the scope of POSI.
It was decided by the POSI group to start with patients with bone metastases because it is the most common reason for RT, and clinicians frequently witnessed unmet supportive care needs among these patients. In May 2013, POSI began collecting PRO at all six BCCA centres: Abbotsford Centre, 
Statistical methods
Descriptive statistics were used to present accrual and utility of PRO data. Comparison in accrual rates between categories was performed with w 2 tests. Mean and median differences in time RNs spend on POSI follow-up phone calls were compared with t tests and w 2 tests, respectively. Multivariable logistic regression modelling was used to evaluate the association between numerous factors and successful accrual or not. P values were two sided, and values less than .05 were considered statistically significant. Analyses were conducted using SPSS version 19.0 software (Chicago, Illinois). Figure 1 highlights key milestones through POSI. From May 2013 to July 2015, patients were approached by POSI on 20,150 encounters, while 17,101 (85%) were successfully accrued. A similar initiative as POSI which collected PRO from patients with prostate cancer amalgamated with POSI in 2016, which brought the POSI database to 28,068 patients enrolled, though for the purpose of this article the prostate cancer patients are excluded. The accrual rate for all encounters was 85%, with the accrual rate varying between 78% and 89% depending on the cancer centre (P < .001) and the tumour site (Figure 2 ; P < .001). The absolute accrual is steadily increasing as POSI expands, while the proportion accrued remains relatively stable. There is variability in accrual across the different centres, which is multifactorial; for example, VIC decided in the third quarter of 2014 that they would not participate until patient tablet entry was available, leading to no accruals in the last quarter of 2014, but then an increase once tables were available, but a subsequent decline because of lack of engagement of centre leadership, which is an ongoing issue (Figure 3) . 
Results
Feasibility: Accrual rates
Feasibility: Resources required
Funding from two grants was used during the study period, in an amount of $382,000, which was used primarily for funding personnel. Up front personnel time included time to plan and implement basic infrastructure for POSI (eg, server setup, database design, application interface with electronic medical record; *6 weeks full time equivalent [FTE] ). Subsequent expansion took approximately 2 weeks FTE per tumour site. Other personnel costs included administrative support (one person at 0.5 full time equivalent), financing time for meetings, and POSI team leads at each centre to work out centre-specific difficulties in accrual. Only a small portion of the funds went toward hardware (eg, tablets) as most computer equipment was supported in-kind from the BCCA, as was physician and investigator time. Based on the self-report of RN time on phone calls, approximately 700 RN hours have been utilized to support the 4,911 patients called through POSI, which is less than 1 day per week of RN time at each centre.
Utility: RN-led support driven by PRO
During the study period, 7,911 follow-up phone calls were made by RNs to both collect PRO and subsequently use these PRO to guide follow-up care. These calls were completed in <5, 5 to 10, and >10 minutes in 51%, 30%, and 19% of the cases, respectively (Figure 4) . The RN-reported time to complete the follow-up call varied significantly by RT site (P < .001), with the longest time required for patients with brain metastases (Figure 4) .
Registered nurses self-reported that 1,243 (25%) of the phone calls through POSI offered some sort of support. The RN phone calls were significantly longer for patients who were offered any support (eg, symptom management, referral to family physician) by an RN versus those who were not (median 8 vs 4 minutes; P < .001).
Utility: Population-based PRO data guiding change in care
We demonstrated that PRO data can be used for QI initiatives. As an example, data from POSI identified that a proportion of patients with self-reported symptoms of depression were not being referred to counselling services and that some frontline staff had a difficult time asking depression screening questions. We subsequently created an electronic PRO collection system, linked to an electronic dashboard with automated flagging to guide counsellor's follow-up interventions. 18 As an additional example, brain metastases patients approached through POSI were asked 2 weeks after RT if they were given dexamethasone weaning instructions. By auditing this question, we were able to determine that there was variability in patients' awareness of dexamethasone weaning instructions across the five BCCA centres accruing patients with brain metastases at the time, and we were subsequently able to inform local radiation oncology leads, who led local interventions to increase distribution of dexamethasone weaning instructions post-RT. The integration of PRO data collection and research in the practice setting resulted in direct feedback to clinicians and change in RT practice, even at this initial phase. For example, using comparative effectiveness research through POSI, we demonstrated similar patient-reported improvements in pain, function, and distress for patients treated with either singlefraction or costlier multiple-fraction RT for bone metastases on a population level. 19 This subsequently helped to increase the evidence-based prescription of single-fraction RT for bone metastases within British Columbia. 20 
Discussion
This large provincial initiative demonstrates it is feasible to collect PRO on a population-based scale. We believe the most important reason for POSI's success was the engagement of frontline staff, including volunteer "champions," and giving leadership roles to frontline care nurses and radiation therapists at all regional centres. Importantly, this initiative has demonstrated that PRO can be collected and utilized for clinical care, QI, and research with only a modest increase in workload and resource investment.
Several lessons have been learned through our provincial development of POSI. The initial survey collection proved very useful to remind frontline staff of their self-reported commitment to POSI, whenever accrual decreased or difficulty with expansion arose. In addition, we learned that asking radiation therapists to screen for depression in person, which is generally not within the scope of their training program, was a poor choice and that we should include expert counsellors in future decisions regarding distress screening. Finally, we discovered that adopting a flexible approach to data collection allowed each centre to come up with unique solutions that they could subsequently share with other centres.
The POSI experience suggests that the resources required to collect PROs are not prohibitive and that several approaches can be adopted to make PRO collection feasible. Patient-reported outcome implementation issues identified in the literature that are particularly relevant to the cancer care context include limiting patient burden and completion time (eg, keeping questions under 20 items or 10 minutes), collecting baseline and selected follow-up times while minimizing the number of assessments, and keeping data collection in an easy-to-use electronic format. 21 The high accrual rate achieved by POSI suggests that the time commitment was acceptable to patients even among palliative patients. Prospective Outcomes and Support Initiative demonstrated that the PRO could be utilized for immediate clinical care and also to change practice long term as a QI and research tool.
This report should be interpreted in the context of its strengths and limitations. As a strength, we demonstrated that province-wide implementation of PRO collection and utilization is feasible in the real world, non-clinical trial setting, despite differences between centres. Unfortunately, data were not yet collected on physician time saved. However, by tailoring the collection of PRO data collected to the tumour type being treated (eg, lung: cough, shortness of breath, hemoptysis; gynecological: urinary, bowel, sexual function) rather than collecting generic symptoms, the data are more sensitive to detect differences in PRO that are most pertinent to tumour type. With further long-term collection of patient-reported symptoms and side effects specific to a tumour site being treated, we plan to assess the relationships between radiation doses to normal tissues (eg, salivary glands) and the resultant side effect (eg, xerostomia), which has the potential to fill knowledge gaps and guide radiation treatment planning internationally. 22 
Conclusion
Province-wide collection and utilization of PRO for clinical care, QI, and research are feasible and can be associated with only a modest increase in resources and workload. Enabling frontline care providers to champion the development of a PRO collection program appears to improve acceptance and ensures the program is not only useful to administrators but also to daily users who in turn improve accrual.
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